Publications
Text queries can be conducted by Author, Title, or Keyword.
Orbital and dorsolateral frontal perfusion defect associated with
behavioral response to cholinesterase inhibitor therapy in Alzheimer's
Disease
Source: Journal of Neuropsychiatry and Clinical Neurosciences 2000 May;12(2):209-218.
Author: Mega MS, Dinov ID, Lee L, O'Connor SM, Masterman DM, Wilen B, Mishkin F, Toga AW, Cummings JL.
PubMed ID: 11001599
Abstract:
The authors retrospectively explored the behavioral and functional imaging profile of Alzheimer's disease (AD) patients who respond to cholinesterase inhibitor therapy by using the Neuropsychiatric Inventory (NPI) and baseline [99mTc]HMPAO SPECT. Thirty AD patients were divided into three groups (Responders, Nonresponders, and Unchanged) based on their behavioral response to donepezil. Responders had significantly (P < or = 0.01) more pretreatment irritability, disinhibition (P < or = 0.05), and euphoria (P = 0.05) than Nonresponders and significantly lower lateral orbital frontal (P < 0.00001) and dorsolateral frontal (P < or = 0.0005) perfusion bilaterally. A pretreatment orbitofrontal syndrome may predict behavioral response to cholinesterase inhibitor therapy in AD.
Source: Journal of Neuropsychiatry and Clinical Neurosciences 2000 May;12(2):209-218.
Author: Mega MS, Dinov ID, Lee L, O'Connor SM, Masterman DM, Wilen B, Mishkin F, Toga AW, Cummings JL.
PubMed ID: 11001599
Abstract:
The authors retrospectively explored the behavioral and functional imaging profile of Alzheimer's disease (AD) patients who respond to cholinesterase inhibitor therapy by using the Neuropsychiatric Inventory (NPI) and baseline [99mTc]HMPAO SPECT. Thirty AD patients were divided into three groups (Responders, Nonresponders, and Unchanged) based on their behavioral response to donepezil. Responders had significantly (P < or = 0.01) more pretreatment irritability, disinhibition (P < or = 0.05), and euphoria (P = 0.05) than Nonresponders and significantly lower lateral orbital frontal (P < 0.00001) and dorsolateral frontal (P < or = 0.0005) perfusion bilaterally. A pretreatment orbitofrontal syndrome may predict behavioral response to cholinesterase inhibitor therapy in AD.